Shares of Calyxt, Inc. (NASDAQ:CLXT) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $29.05.
A number of research firms recently commented on CLXT. Zacks Investment Research upgraded Calyxt from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Ladenburg Thalmann Financial Services began coverage on Calyxt in a research report on Wednesday, December 20th. They set a “buy” rating and a $34.25 price objective for the company. Citigroup dropped their price objective on Calyxt from $27.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, November 16th. Jefferies Group lifted their price objective on Calyxt to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on Calyxt in a research report on Monday, October 30th. They set an “outperform” rating and a $32.00 price objective for the company.
A number of large investors have recently modified their holdings of the business. American International Group Inc. acquired a new stake in Calyxt in the 3rd quarter worth about $133,000. California State Teachers Retirement System acquired a new stake in Calyxt in the 3rd quarter worth about $323,000. Schwab Charles Investment Management Inc. acquired a new stake in Calyxt in the 3rd quarter worth about $358,000. Finally, Bank of New York Mellon Corp acquired a new stake in Calyxt in the 3rd quarter worth about $542,000. 21.13% of the stock is currently owned by hedge funds and other institutional investors.
Calyxt (NASDAQ:CLXT) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.35). Calyxt had a negative return on equity of 101.69% and a negative net margin of 5,969.52%. analysts expect that Calyxt will post -1.07 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Calyxt, Inc. (CLXT) Receives Consensus Rating of “Buy” from Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/08/calyxt-inc-clxt-receives-consensus-rating-of-buy-from-brokerages.html.
Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.